In February 2026, Novo Nordisk announced that the US Food and Drug Administration has approved Ozempic tablets, an oral form of semaglutide, with availability expected in the United States in the second quarter of 2026
Hundreds of genes responsible for synaptic transmission, learning, and behavior are deregulated in CdLS patients [391]
People regain weight four times faster after stopping GLP-1 weight-loss drugs compared to diet and exercise programmes, with participants regaining 10 kg within a year after stopping medication
Led by Duke scientist Jonathan Campbell, PhD, the team of obesity and diabetes researchers analyzed pancreatic tissue from both mice and humans across a range of ages, body weights, and diabetes statuses
Let's listen to another listener